XML 21 R10.htm IDEA: XBRL DOCUMENT v3.25.3
Earnings Per Share
9 Months Ended
Sep. 30, 2025
Earnings Per Share [Abstract]  
Earnings Per Share
Note 2 — Earnings Per Share
Basic and diluted earnings per common share are calculated using the treasury method. Under the treasury method, basic earnings per share is calculated as net income divided by the weighted average number of common shares outstanding during the period. Diluted earnings per share includes the dilutive effect of additional potential common shares issuable under the Company’s stock and incentive compensation plans. Information regarding the Company’s basic and diluted earnings per common share is presented in the following table:
(Dollars in thousands, except per share amounts)Three Months Ended September 30,Nine Months Ended September 30,
Numerator:2025202420252024
Net income$8,623 $18,601 $45,681 $62,222 
Denominator:
Weighted average common shares outstanding31,183,092 31,130,293 31,193,739 31,051,672 
Dilutive effect of stock-based awards180,479 109,584 188,271 109,195 
Weighted average diluted common shares outstanding31,363,571 31,239,877 31,382,010 31,160,867 
Basic earnings per common share$0.28 $0.60 $1.46 $2.00 
Diluted earnings per common share0.27 0.60 1.46 2.00 
There were 38,564 and 100,706 weighted average shares of anti-dilutive stock-based awards excluded from the calculation of earnings per share for the three and nine months ended September 30, 2025, respectively, primarily due to the exercise price, grant date fair value or purchase price of the stock awards exceeding the average market price of the Company’s stock during the respective periods. There were 330,263 and 412,390 weighted average shares of anti-dilutive stock-based awards excluded from the calculation of earnings per share for the three and nine months ended September 30, 2024, respectively, primarily due to the exercise price, grant date fair value or purchase price of the stock awards exceeding the average market price of the Company’s stock during the respective periods.